• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Oncorus Inc.

    8/3/23 5:00:26 PM ET
    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ONCR alert in real time by email
    15-12G 1 d511808d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number: 001-39575

     

     

    Oncorus, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    c/o Verdolino & Lowey, P.C.

    124 Washington Street, Ste. 101

    Foxborough,

    Massachusetts 02035

    (508) 543-1720

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, par value $0.0001 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: 125

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, Oncorus, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

        ONCORUS, INC.
    Date: August 3, 2023     By:  

    /s/ Brian J. Shea

        Name:   Brian J. Shea
        Title:   President and Interim Chief Executive Officer
    Get the next $ONCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Oncorus Inc.

      DEFA14A - Oncorus, Inc. (0001671818) (Filer)

      8/7/23 6:52:07 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by Oncorus Inc.

      15-12G - Oncorus, Inc. (0001671818) (Filer)

      8/3/23 5:00:26 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Oncorus Inc.

      DEFA14A - Oncorus, Inc. (0001671818) (Filer)

      7/28/23 4:40:36 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncorus Announces Workforce Reduction Plan

      ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company's board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus' workforce, which is expected to be completed by August 2023. Theodore (Ted) Ashburn, M.D., Ph.D. (Chief Executive Officer), Stephen W. Harbin (C

      6/1/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

      IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

      5/22/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

      Research collaboration leverages Oncorus' proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong's mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle

      1/4/23 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

      IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

      5/22/23 4:05:00 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Appoints Douglas Fambrough to Board of Directors

      -Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. "We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer

      6/23/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

      CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. "We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previ

      5/10/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Financials

    Live finance-specific insights

    See more
    • Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

      Company now focused on the development of ONCR-021, Oncorus' lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company's cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeli

      11/30/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

      Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncolytic viral expression in combination with immune checkpoint inhibitorsAdditional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Continued to advance preclinical programs, including ONCR-021 towards IND filing in mid-2023Strengthened executive leadership team with promotion of John Goldberg, M.D., to Chief Medical Office

      3/9/22 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021

      ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumorsRecommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is underwayThree of eight evaluable patients at RP2D across multiple indications (cutaneous melanoma, head and neck cancer, and mucosal melanoma) experienced clinical benefit after two doses of single-agent ONCR-177Proof of principle established for propriety Herpes Simplex Virus (HSV) platform that leverages microRNA attenuation to enable interferon resistance via retention of γ34.5 and five complementary immunomo

      11/12/21 7:00:00 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/14/23 8:02:36 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/13/23 12:36:32 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Oncorus Inc. (Amendment)

      SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

      2/2/23 2:15:07 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Shea Brian J. claimed ownership of 8,541 shares

      3 - Oncorus, Inc. (0001671818) (Issuer)

      6/16/23 9:20:42 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Nolte Alexander

      3 - Oncorus, Inc. (0001671818) (Issuer)

      5/22/23 5:00:27 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Flynn James E sold $88,254 worth of shares (336,235 units at $0.26)

      4 - Oncorus, Inc. (0001671818) (Issuer)

      12/30/22 7:16:31 PM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ONCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Oncorus with a new price target

      Maxim Group initiated coverage of Oncorus with a rating of Buy and set a new price target of $35.00

      3/16/21 7:41:50 AM ET
      $ONCR
      Medicinal Chemicals and Botanical Products
      Health Care